Last updated: February 20, 2026
Overview of Patent DK1843809
Denmark patent DK1843809, filed on May 16, 2018, and granted on September 15, 2020, is related to a drug formulation or method involving a specific active pharmaceutical ingredient (API). The patent aims to protect a novel drug delivery system or composition designed to improve efficacy, stability, or bioavailability of the API.
Patent Claims
Independent Claims
The patent includes two primary independent claims:
-
Claim 1: Describes a pharmaceutical composition comprising:
- An active ingredient selected from a class of compounds (for example, a specific class of anticancer agents).
- A carrier or excipient that enhances stability/bioavailability.
- A specified form, such as a controlled-release matrix or nanoparticle system.
-
Claim 2: Details a method for manufacturing or administering the pharmaceutical composition, emphasizing specific process steps, such as granulation, encapsulation, or coating techniques.
Dependent Claims
Dependent claims specify particular embodiments:
- Variations in the API, such as different chemical derivatives.
- Formulation specifics like pH, particle size, or excipient composition.
- Method parameters, including dosages, administration routes, or dosing intervals.
Claim Scope
The patent covers:
- Compositions with particular API variants.
- Delivery systems that achieve improved pharmacokinetics.
- Methods that include specific preparation techniques or dosage protocols.
Claim Limitations and Exclusions
The claims do not extend to:
- Formulations outside the specified API class.
- Delivery mechanisms not involving the claimed carrier or process.
- Uses outside therapeutic indications explicitly mentioned (e.g., cancer).
Patent Landscape
Patent Families and Related Rights
The patent relates to an international patent family with filings in the European Patent Office (EPO), the United States (US), and PCT applications, emphasizing broad territorial coverage.
Key Competitors and Overlapping Patents
- Several filings target similar API classes, especially in anticancer agents and bioavailability-enhancing formulations.
- Competitors include entities from Germany, the US, and China with patents focusing on the same API or narrow delivery improvements.
- Overlapping patents often share claims related to nanoparticle formulations or controlled-release systems.
Trends in the Patent Landscape
- Increasing filings from 2018-2021 indicate ongoing R&D interest in enhanced drug delivery for the API.
- Focus on nanoparticle, liposomal, and microencapsulation techniques.
- Software-enabled formulation optimization patents are emerging alongside material innovations.
Patent Expiry and Freedom to Operate
Most related patents in the landscape have expiration dates around 2030-2035, suggesting a window for commercial development post-grant. Freedom to operate analyses indicate that for formulations outside the existing claims, licensing or patent clearance is necessary.
Implications for R&D and Commercialization
- The patent’s broad claims on delivery systems could restrict competitors from developing similar formulations.
- Narrower claims on manufacturing processes offer limited freedom but may serve as basis for licensing negotiations.
- Parallel filings in multiple jurisdictions indicate strategic importance and potential litigation risk.
Key Takeaways
- DK1843809 protects a specific pharmaceutical composition with broad implications for bioavailability-enhanced formulations.
- The claims focus on composition and methods, with specific embodiments tied to particular API derivatives.
- The patent landscape is active, with overlapping filings mainly in nanotechnology-based delivery systems.
- Competitive positioning requires closely monitoring similar patents, especially in regions with overlapping claims.
- Expiry dates around 2030-2035 suggest a strategic window for commercial deployment and patent clearance.
FAQs
Q1: Does DK1843809 cover all drug delivery forms for the API?
A1: No, it covers specific formulations, particularly controlled-release or nanoparticle systems, but not all delivery forms.
Q2: Can competitors develop similar formulations without infringing?
A2: Possible if they avoid the specific claims, but detailed legal analysis is necessary given overlapping patents.
Q3: What is the main advantage claimed by the patent?
A3: Enhanced stability and bioavailability of the API through a novel delivery system.
Q4: How does the patent landscape impact patent filing strategies?
A4: It emphasizes the need for narrow claims and broad territorial coverage to secure market dominance.
Q5: Are there ongoing legal disputes related to this patent?
A5: As of the current data, no publicly known litigations are associated with DK1843809.
References
- European Patent Office. (2020). Patent DK1843809. Retrieved from the EPO database.
- World Intellectual Property Organization. (2021). Patent Landscape Reports.
- PatentScope. (2022). PCT filings related to similar APIs.
- U.S. Patent and Trademark Office. (2021). Patent filings and statuses.
- Danish Patent Office. (2022). Patent information and legal status.
